Tomas R Ganz from 168 Cliffwood Ave, Los Angeles, CA 90049, age 76, Phone: (310)3863054

Dr. Tomas Ganz, Los Angeles CA - MD (Doctor of Medicine)

view source

Specialties:

Pulmonology

Address:

200 Medical Plz Suite 214, Los Angeles, CA 90095
(310)8250631 (Phone)

Certifications:

Internal Medicine, 1981
Pulmonary Disease, 1984

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
University of California At Los Angeles
Graduated: 1978
Medical School
Ronald Reagan UCLA Medical Center
Graduated: 1978

Tomas Ganz, Los Angeles CA

Work:

Ucla Chs. 37 055
200 Medical Plaza, Los Angeles, CA 90024
Ucla Chs. 37 055
10833 Le Conte Ave, Los Angeles, CA 90095

Us Patents

Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
view source
US Patent:

6716813, Apr 6, 2004
Filed:

Nov 27, 2001
Appl. No.:

09/998547
Inventors:

David J. Lim - Pasadena CA
Paul Webster - Pasadena CA
Ali Andalibi - Studio City CA
Jian-Dong Li - Glendale CA
Tomas Ganz - Los Angeles CA
Assignee:

House Ear Institute - Los Angeles CA
International Classification:

A61K 3800
US Classification:

514 2, 514 12
Abstract:

Disclosed herein is a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin and defensins, were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
view source
US Patent:

7060674, Jun 13, 2006
Filed:

Apr 6, 2004
Appl. No.:

10/819714
Inventors:

David J. Lim - Pasadena CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Studio City CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Assignee:

House Ear Institute - Los Angeles CA
International Classification:

A61K 38/00
US Classification:

514 2, 514 12
Abstract:

Disclosed herein is a composition and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
view source
US Patent:

7338936, Mar 4, 2008
Filed:

Oct 22, 2004
Appl. No.:

10/971559
Inventors:

David J. Lim - Pasadena CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Assignee:

House Ear Institute - Los Angeles CA
International Classification:

A61K 38/17
C07K 14/435
US Classification:

514 12, 530324
Abstract:

The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.

Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
view source
US Patent:

7534764, May 19, 2009
Filed:

Jun 28, 2006
Appl. No.:

11/427095
Inventors:

Tomas Ganz - Los Angeles CA, US
Lan Lin - Los Angeles CA, US
Yigal P. Goldberg - Vancouver, CA
Assignee:

The Regents of the University of California - Oakland CA
Xenon Pharmaceuticals, Inc. - Burnaby, British Columbia
International Classification:

A61K 38/00
US Classification:

514 12
Abstract:

Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.

Competitive Regulation Of Hepcidin Mrna By Soluble And Cell-Associated Hemojuvelin
view source
US Patent:

7745407, Jun 29, 2010
Filed:

Mar 4, 2009
Appl. No.:

12/397589
Inventors:

Tomas Ganz - Los Angeles CA, US
Lan Lin - Beijing, CN
Yigal P. Goldberg - Vancouver, CA
Assignee:

The Regents of the University of California - Oakland CA
Xenon Pharmaceuticals Inc. - Burnaby, British Columbia
International Classification:

C12Q 1/68
A61K 38/00
US Classification:

514 12, 435 6
Abstract:

Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.

Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
view source
US Patent:

7985729, Jul 26, 2011
Filed:

Apr 21, 2010
Appl. No.:

12/764852
Inventors:

David J. Lim - Pasadena CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Assignee:

House Research Institute - Los Angeles CA
International Classification:

A61P 31/04
A61K 38/17
C07K 14/435
US Classification:

514 24, 514 213, 530300
Abstract:

The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.

Mini-Hepcidin Peptides And Methods Of Using Thereof
view source
US Patent:

8435941, May 7, 2013
Filed:

Dec 4, 2009
Appl. No.:

13/131792
Inventors:

Tomas Ganz - Los Angeles CA, US
Elizabeta Nemeth - Los Angeles CA, US
Gloria Preza - Los Angeles CA, US
Piotr Pawel Ruchala - Los Angeles CA, US
Assignee:

The Regents of the University of California - Oakland CA
International Classification:

A61K 38/04
US Classification:

514 54, 514 135, 514 218, 514 217, 514 216
Abstract:

Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Use Of Antimicrobial Proteins And Peptides For The Treatment Of Otitis Media And Paranasal Sinusitis
view source
US Patent:

20070207963, Sep 6, 2007
Filed:

May 18, 2007
Appl. No.:

11/750542
Inventors:

David Lim - Pasadena CA, US
Paul Webster - Pasadena CA, US
Ali Andalibi - Altadena CA, US
Jian-Dong Li - Glendale CA, US
Tomas Ganz - Los Angeles CA, US
Kiweon Cha - Irvine CA, US
Assignee:

HOUSE EAR INSTITUTE - Los Angeles CA
International Classification:

A61K 38/16
US Classification:

514012000
Abstract:

The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.

Tomas Ganz

Chief Medical Officer At Intrinsic Lifesciences Llc Professor At Ucla

view source

Location:

Greater Los Angeles Area

Industry:

Research

Experience:

Intrinsic LifeSciences LLC (Privately Held; 1-10 employees; Biotechnology industry): Chief Medical Officer, (January 2007-Present) Iron- and anemia-related diagnosticsUCLA (Educational Institution; 10,001+ employees; Research industry): Professor, (1983-Pre...